Company intelligence / Profile preview
Inthera Bioscience AG
Zurich, Zurich, Switzerlandintherabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Inthera Bioscience’s lead molecule, INTH‑454, is a new chemical entity that inhibits DNA replication and cell cycle control in tumor cells. It is currently in late preclinical development and has shown efficacy against cancer cells with high proliferation rates. The company’s approach merges the versatility of small molecules with the specificity of biologics to target previously “undruggable” intracellular targets relevant to oncology. No clinical results have been published yet as programs are not yet in human trials
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
M Ventures (investor/partner)No major pharma partnerships publicly disclosed.
Beyond the preview
Go deeper on Inthera Bioscience AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inthera Bioscience AG.